Bolt Biotherapeutics, Inc. (BOLT)
Largest Insider Buys in Sector
BOLT Stock Price History Chart
BOLT Stock Performance
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
Insider Activity of Bolt Biotherapeutics, Inc.
Over the last 12 months, insiders at Bolt Biotherapeutics, Inc. have bought $0 and sold $0 worth of Bolt Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Bolt Biotherapeutics, Inc. have bought $18.6M and sold $622,818 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,500 shares for transaction amount of $7,125 was made by Quinn William P. (Chief Financial Officer) on 2023‑12‑12.
List of Insider Buy and Sell Transactions, Bolt Biotherapeutics, Inc.
| 2023-12-12 | Chief Financial Officer | 7,500 0.0291% | $0.95 | $7,125 | -23.88% | |||
| 2023-12-06 | Chief Financial Officer | 2,500 0.008% | $0.78 | $1,955 | -17.59% | |||
| 2023-11-30 | Sale | director | 123,079 0.4308% | $0.86 | $105,614 | -10.81% | ||
| 2023-11-29 | Sale | director | 25,805 0.0954% | $0.91 | $23,379 | -14.79% | ||
| 2023-11-21 | Sale | director | 1,943 0.0071% | $0.90 | $1,751 | -10.77% | ||
| 2023-11-21 | Sale | 10 percent owner | 3,400 0.0125% | $0.90 | $3,060 | -10.77% | ||
| 2023-11-20 | Sale | director | 31,257 0.1173% | $0.92 | $28,756 | -15.33% | ||
| 2023-11-20 | Sale | 10 percent owner | 54,700 0.2053% | $0.92 | $50,324 | -15.33% | ||
| 2023-11-17 | Sale | director | 9,345 0.0354% | $0.93 | $8,691 | -16.40% | ||
| 2023-11-17 | Sale | 10 percent owner | 16,354 0.062% | $0.93 | $15,209 | -16.40% | ||
| 2023-11-16 | Sale | director | 8,571 0.0336% | $0.96 | $8,228 | -16.84% | ||
| 2023-11-16 | Sale | 10 percent owner | 15,000 0.0587% | $0.96 | $14,400 | -16.84% | ||
| 2023-06-06 | Chief Financial Officer | 1,829 0.0088% | $1.18 | $2,161 | -31.48% | |||
| 2022-07-13 | Sale | 800,000 6.5259% | $2.00 | $1.6M | -40.32% | |||
| 2021-12-08 | Chief Financial Officer | 5,000 0.0962% | $4.71 | $23,575 | -56.78% | |||
| 2021-12-06 | Chief Financial Officer | 35 0.0007% | $4.64 | $162 | -55.82% | |||
| 2021-12-06 | Chief Medical Officer | 411 0.0078% | $4.64 | $1,907 | -55.82% | |||
| 2021-06-04 | Chief Financial Officer | 1,221 0.0829% | $16.65 | $20,330 | -50.69% | |||
| 2021-06-04 | Chief Medical Officer | 917 0.0623% | $16.65 | $15,268 | -50.69% | |||
| 2021-02-09 | Sale | director | 62 0.0051% | $20.00 | $1,240 | -58.82% |
Insider Historical Profitability
| Novo Holdings A/S | 3703991 9.6778% | $0.51 | 1 | 1 | <0.0001% | |
| HEALY JAMES | director | 2754437 7.1968% | $0.51 | 1 | 0 | <0.0001% |
| Sofinnova Venture Partners X, L.P. | 10 percent owner | 2754437 7.1968% | $0.51 | 1 | 0 | <0.0001% |
| SHAH MAHENDRA | director | 1448286 3.7841% | $0.51 | 0 | 1 | |
| ENGLEMAN EDGAR | director | 251522 0.6572% | $0.51 | 1 | 7 | <0.0001% |
| Vivo Capital VIII, LLC | 10 percent owner | 111662 0.2918% | $0.51 | 1 | 5 | <0.0001% |
| Quinn William P. | Chief Financial Officer | 36272 0.0948% | $0.51 | 7 | 0 | <0.0001% |
| Schatzman Randall C | Chief Executive Officer | 1500 0.0039% | $0.51 | 1 | 0 | <0.0001% |
| Perez Edith A. | Chief Medical Officer | 1328 0.0035% | $0.51 | 2 | 0 | <0.0001% |
| LAPORTE KATHLEEN | director | 1200 0.0031% | $0.51 | 1 | 0 | <0.0001% |
| Khanna Ashish Siri Ram | director | 1200 0.0031% | $0.51 | 1 | 0 | <0.0001% |